v3.25.2
Subsequent Events (Details Narrative) - USD ($)
 6 Months Ended
Aug. 13, 2025
Jun. 30, 2025
Jul. 31, 2025
Jun. 30, 2024
Debt Instrument [Line Items]        
Principal amount      
Investment and joint venture description   Company would own 10 million shares of NuroMena and contribute a license to its technology to NuroMena, and the Investor will purchase 2.5 million shares of NuroMena for a subscription price of $400,000 (“Initial Investment”). Following the formation of the entity and closing of the Initial Investment, the Investor shall source one or more future investors to purchase up to $50.0 million at $25/share in common stock of the Company, of which 70% of the proceeds will be maintained by the Company and 30% will be transferred to an operating entity to be formed under NuroMena, to conduct clinical trials in the middle-east markets.    
Convertible Debt [Member]        
Debt Instrument [Line Items]        
Principal amount     $ 5,000,000  
Proceeds from issuance of promissory notes $ 4,000,000